Phase II Study Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy Early Stage, Low Volume in Prostate Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess the late toxicity outcomes
focal brachytherapy in patients with low risk prostate cancer This study will utilize the toxicity grading scale Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
6 months to 2 years
Yes
Michael Zelefsky, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
11-056
NCT01354951
May 2011
May 2014
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |